Rain Therapeutics (RAIN) has released an update to notify the public and investors about listing compliance status.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The company has informed Nasdaq of the completion of a merger, requesting the suspension of trading of its shares from January 26, 2024, and the delisting and deregistration of shares from Nasdaq in accordance with the Securities Exchange Act of 1934. Additionally, the company plans to terminate the registration of the shares and suspend reporting obligations by filing the necessary forms with the SEC.
For further insights into RAIN stock, check out TipRanks’ Stock Analysis page.